Skip to Content
Header image


Microbiome-based therapies have been a hot area of research for the last decade and promising early-stage therapies are in clinical development. While these are great opportunities in this space to address patients’ unmet medical needs in a variety of diseases including oncology, immunology and metabolic disorders, there are significant challenges associated with delivering microbiome derived therapies to patients. Halloran has partnered with biotechs that are leading the development of these therapies and help them transverse preclinical, toxicology, clinical and regulatory challenges. Halloran is in forefront collaborating with researchers, CROs, federal agencies in developing unique solutions for this novel, unexplored but highly promising therapeutic area.